“…The metabolic substrate-based studies described in this paper depend on the ability to introduce high levels of flux into the sialic acid biosynthetic pathway with negligible cytotoxicity and minimal growth inhibition. We previously achieved these objectives in other human (and rodent) cells using ‘high-flux’ 1,3,4-O-butanoylated ManNAc analogs [ 40 , 46 , 70 , 71 ] but the cytotoxicity of the newly-synthesized, alkyne-modified analog 1,3,4-O-Bu 3 ManAl was unknown; moreover, the three cell lines used in this study (MCF10A, T-47D and MDA-MB-231) had not been comparatively screened with these analogs in ‘assay media’ where the cells were grown in low serum (1.0%; to prevent recycling of sialic acids from glycoproteins contained in serum [ 57 ]) as well as without antibiotics (to avoid inhibition of sialylation [ 59 ]). Therefore, as a prelude to subsequent metabolic profiling, we first evaluated cell viability by measuring proliferation after treatment with 0, 10, 100, or 250 μM of 1,3,4-O-Bu 3 ManNAc (Panel A in S2 Fig ), 1,3,4-O-Bu 3 ManNAz (Panel B in S2 Fig ), or 1,3,4-O-Bu 3 ManNAl (Panel C in S2 Fig ) for 6, 24, or 48 h and observed no statistically-significant differences between the control and test cells.…”